Latest Market News

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Austin Engineering Limited reported a robust 22.2% increase in revenue for FY25, alongside a mixed earnings performance and fully franked dividends.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Vulcan Steel is set to acquire Roofing Industries for NZ$88 million, marking a strategic entry into New Zealand’s steel roofing market. The deal is backed by an A$87 million equity raise, positioning Vulcan for growth in building materials.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Vulcan Steel Limited reported a 10.9% revenue decline in FY25 alongside a 24.1% drop in adjusted EBITDA, while announcing a fully underwritten NZ$96 million equity raise to fund the acquisition of Roofing Industries Limited. The deal marks Vulcan’s strategic entry into the New Zealand steel roofing and cladding market with expected earnings accretion and no change to its dividend policy.

Vulcan Steel reported a sharp decline in profits for FY25 amid challenging economic conditions but managed to reduce net debt and push forward its hybrid site strategy.

Veris Limited has reported a significant turnaround in FY25, posting a $2 million profit before tax on $97.2 million revenue, driven by growth in digital and spatial advisory services and strategic acquisitions.

Veris Limited has returned to profitability in FY25, driven by strong growth in its digital and spatial advisory services, while declaring its first dividend in years and strengthening its cash position.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Veris Limited has reported a significant financial turnaround for the year ended June 2025, returning to profitability and boosting earnings, while strategically acquiring Spatial Vision to broaden its geospatial services across Australia.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.